Why does hormone therapy protect the heart only when started early?

Cardiology and menopause researchers use the term "timing hypothesis" to describe a real, researched pattern: the same interventions for cardiovascular risk, particularly hormone therapy, appear to help when started closer to the menopause transition, and show much less benefit, or even added risk, when started many years after. Two major randomized trials, KEEPS and ELITE, directly tested this by comparing early initiation to later initiation and measuring surrogate markers of cardiovascular disease, including artery wall thickness and coronary artery calcification (Menopause, 2015).

How many years after menopause does heart protection still work?

The research consistently points to a window of roughly the first 6 years after your final period, or before age 60, as the period where cardiovascular benefit from hormone therapy is most clearly demonstrated. Outside that window, the risk-benefit picture shifts meaningfully. A 2025 scientific statement from the American Heart Association specifically addressed how clinicians should think about timing when discussing cardiovascular prevention through the menopause transition, emphasizing that risk assessment and intervention should begin during the transition itself, not be deferred until well after it (Circulation, AHA Scientific Statement, 2025).

Does earlier action help even without hormone therapy?

Even if hormone therapy is not right for you, the underlying idea, that earlier action changes outcomes more than later action, applies more broadly. Vascular changes that begin during the transition are easier to influence before they become established arterial changes. This is part of why cardiovascular risk assessment increasingly is recommended to start during perimenopause, not deferred until a woman is fully postmenopausal or already showing symptoms.

What should I do now about my heart risk?

  • If you are in perimenopause or within a few years of your final period, this is genuinely the highest-leverage window to get a real cardiovascular risk assessment, not something to put off.
  • If you are considering hormone therapy for cardiovascular reasons specifically, timing since your final period is one of the most important factors your doctor will weigh, not just your age alone.
  • If you are already well past this window, that does not mean nothing helps, it means the conversation with your doctor should be framed around your current risk profile rather than assuming early-window findings apply the same way.

My Perspective

I think "it's never too late to start" is well-intentioned but sometimes genuinely misleading advice. The honest, evidence-based picture is that timing matters, real research shows a specific window where intervention does more, and pretending otherwise does not help anyone make a better decision. Knowing this window exists is not meant to create panic if you have already passed it, it is meant to help you actually use it if you have not.

A note from Marilyn: This is education, not medical advice. Whether hormone therapy or other interventions are appropriate for you depends on your full individual risk profile and timing, and should be decided with your own healthcare provider. I am a nutrition specialist, not your physician.

The fuller picture of how estrogen's cardiovascular role changes across the whole transition is in Estrogen Left the Chat: Biohacking Menopause. And Receipts can help you track where you are in your own timeline, which is exactly the context worth bringing to this conversation.

Frequently asked questions

What is the "timing hypothesis" in menopause and heart disease?

It is the researched finding that cardiovascular interventions, particularly hormone therapy, show clearer benefit when started closer to the menopause transition, roughly within 6 years of the final period or before age 60, and a less favorable risk-benefit picture when started later.

Is there a specific window when intervention matters most?

Research points to roughly the first 6 years after the final menstrual period, or before age 60, as the window where cardiovascular benefit from early intervention is most clearly demonstrated in major trials like KEEPS and ELITE.

Does this only apply to hormone therapy?

The clearest trial evidence is about hormone therapy specifically, but the underlying principle, that earlier vascular changes are easier to influence than established ones, is part of why cardiovascular risk assessment is increasingly recommended to start during perimenopause more broadly.

What if I am already past this window?

It does not mean intervention is pointless, it means the conversation with your doctor should be based on your current individual risk profile rather than assuming the early-window research applies identically. Risk reduction remains meaningful outside the window, just through a different lens.